Growth Hormone
Sermorelin
GHRH(1–29) analogue that stimulates pulsatile endogenous growth hormone release.
- Half-life
- ~11–12 minutes (very short)
- Route
- Subcutaneous, evening dosing preferred
Overview
Sermorelin is the biologically active 29-amino-acid N-terminal fragment of growth-hormone-releasing hormone. Historically FDA-approved (Geref) for paediatric growth-hormone deficiency; the branded product has been discontinued but compounded versions remain in use.
Mechanism of action
Binds pituitary GHRH receptors to stimulate physiologic, pulsatile GH release, preserving negative feedback and reducing the desensitisation seen with exogenous GH.
Evidence base
Adult trials show modest increases in IGF-1, lean mass and sleep quality. Preserves the natural GH pulse pattern better than direct GH administration.
Typical dosing
Adult research protocols commonly 100–300 mcg subcutaneously at bedtime, 5 nights per week, in 3–6 month cycles. Open the dose calculator →
Safety & contraindications
Injection-site reactions are the most common effect. Long-term data are limited; contraindicated in active malignancy.
Common stacks
Frequently combined with a GHRP (ipamorelin) for synergistic pulse amplification.
Related peptides
Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.